Skip to content

Kymera Therapeutics KYMR Other long-term liabilities

Other long-term liabilities at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Kymera Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's other long-term liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's other long-term liabilities?
Kymera Therapeutics (KYMR) reported other long-term liabilities of $4.5K in Q4 2025.
How has Kymera Therapeutics's other long-term liabilities changed year-over-year?
Kymera Therapeutics's other long-term liabilities increased by 105.8% year-over-year, from -$77.5K to $4.5K.
What is the long-term trend for Kymera Therapeutics's other long-term liabilities?
Over 4 years (2021 to 2025), Kymera Therapeutics's other long-term liabilities has grown at a -32.4% compound annual growth rate (CAGR), from $86K to $18K.